TD Waterhouse Canada Inc. Reduces Stake in Sanofi $SNY

TD Waterhouse Canada Inc. lowered its position in Sanofi (NASDAQ:SNY) by 8.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 219,429 shares of the company’s stock after selling 21,342 shares during the period. TD Waterhouse Canada Inc.’s holdings in Sanofi were worth $9,140,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Advisory Services Network LLC grew its position in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after buying an additional 210 shares during the period. Savant Capital LLC lifted its position in Sanofi by 2.7% during the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after purchasing an additional 225 shares in the last quarter. Wesbanco Bank Inc. lifted its position in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after buying an additional 230 shares in the last quarter. IFG Advisory LLC lifted its holdings in Sanofi by 2.7% during the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after purchasing an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC lifted its stake in shares of Sanofi by 2.9% during the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock valued at $457,000 after buying an additional 263 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Trading Down 0.2%

SNY stock opened at $44.24 on Friday. The firm has a fifty day moving average price of $43.92 and a 200 day moving average price of $44.70. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The firm has a market cap of $107.26 billion, a PE ratio of 23.16, a price-to-earnings-growth ratio of 1.34 and a beta of 0.35. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company had revenue of $13.36 billion for the quarter. During the same period in the previous year, the company earned $3.24 EPS. Sanofi’s revenue for the quarter was up 16.0% compared to the same quarter last year. Sell-side analysts anticipate that Sanofi will post 5.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research analyst reports. Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 29th. Finally, Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.